SLC5A2 and type 2 diabetes mellitus: Similarly, several studies have evaluated the effects of different SGLT2 inhibitors including empagliflozin, dapagliflozin, luseogliflozin, and ipragliflozin EAT in patients with T2DM, both with and without obesity.